What About GnRH?
Leuprolide depot is another high-cost item for hospitals (and presumably a high revenue item for SNY and Abbott). It is usually used in an outpatient setting and it has a considerable retail presence as well. Since it is a synthetic analogue of GnRH, then would MNTA's methods predictably have any value toward developing it?
I'm not asking if MNTA will take on this challenge; I'm just asking is it within the realm of possibility so that this ultra-long can better analyze the MNTA universe of potential longterm projects.
In my realm dosage forms such as depot injections are used by companies to make their product hard to replicate pharmacodynamically (and allegedly to benefit the patient too ;-)). Would that add an added layer to keep a company like MNTA at bay with regard to developing a GnRH FoB?
It appears that many pituitary hormones are glycoproteins or at the very least, from a non-PhD's POV, pseudo-glycoproteins. Perhaps if after MNTA matures they could look at these hormones as potential orphan drug candidates.
Market Data 
Markets 
AI
